董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yong Yan | 男 | Independent Director | 53 | 未披露 | 未持股 | 2026-03-30 |
| Jun Liu | 男 | Chairman of the Board and Chief Executive Officer and Director and President | 62 | 23.27万 | 1123.72 | 2026-03-30 |
| Huijuan Zhong | 女 | Chief Scientific Officer and Director | 59 | 未披露 | 未持股 | 2026-03-30 |
| Xiaohui Hao | 男 | Independent Director | 61 | 未披露 | 未持股 | 2026-03-30 |
| Helen Hsu | 女 | Independent Director | 63 | 未披露 | 未持股 | 2026-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jun Liu | 男 | Chairman of the Board and Chief Executive Officer and Director and President | 62 | 23.27万 | 1123.72 | 2026-03-30 |
| Dian Ying Jing | 女 | Secretary | 59 | 未披露 | 1123.72 | 2026-03-30 |
| Huijuan Zhong | 女 | Chief Scientific Officer and Director | 59 | 未披露 | 未持股 | 2026-03-30 |
| Liqin Xie | 男 | Chief Operating Officer | 54 | 未披露 | 未持股 | 2026-03-30 |
| Ning Zhang | 男 | Chief Technology Officer | 51 | 未披露 | 未持股 | 2026-03-30 |
| Wanjun Zhang | 男 | Chief Financial Officer and Treasurer | 52 | 未披露 | 未持股 | 2026-03-30 |
董事简历
中英对照 | 中文 | 英文- Yong Yan
-
Yong Yan是Alphavest Acquisition Corp的首席执行官，自2014年1月以来，他一直是总部位于上海的V-Stone Capital的合伙人，负责金融科技、区块链、大数据、医疗保健等领域的融资和私募股权投资。在加入四通资本之前，严博士是私募股权基金湖北宏泰产业投资基金的总经理兼CIO。此前，严博士是复星集团的董事总经理，复星集团是中国最大的民营企业集团之一，负责在线金融平台、证券化和金融科技等金融领域的投资，并建立内部的P2P平台。在加入复星集团之前，严博士曾在平安集团旗下的全球最大金融科技公司之一的陆金所担任新产品开发总经理。在2014年初移居中国之前，严博士在华尔街工作了近15年，其中在瑞士信贷工作了10年，担任全球结构性产品市场研究主管。严博士还曾在美林等其他金融公司工作。严博士是纽约TCFA（中国金融协会）的前任会长。他还是北京中关村私募股权&风险投资协会（ZVCA）的副总裁。严先生拥有阿拉巴马大学金融学博士学位，并且是CFA持证人。
Yong Yan has served as a member of the board of directors since the Closing Date. Mr. Yan, AlphaVest's Chief Executive Officer until closing of the Business Combination, has been a partner at the Shanghai based V Stone Capital since January 2014, where he oversees fund raising and private equity investments in FinTech, BlockChain, Big Data, Healthcare and other areas. Prior to joining V Stone Capital, Dr. Yan was the General Manager and CIO of Hubei Hongtai Industrial Investment Fund, a private equity fund of funds. Previously, Dr. Yan was a Managing Director of Fosun Group, one of the largest private conglomerates in China, where he was in charge of investments in the financial sectors, such as online financial platform, securitization and fin tech, as well as building an in house P2P platform. Prior to joining the Fosun Group, Dr. Yan was the General Manager of New Product Development at Lufax, one of the world's largest fintech companies, owned by PingAn Group. Prior to moving to China in early 2014, Dr. Yan worked on Wall Street for almost 15 years, including 10 years at Credit Suisse, as the head of research of the global structured product market. Dr. Yan also worked at other financial firms such as Merrill Lynch. Dr. Yan is the ex President of TCFA (The Chinese Finance Association) in New York. He is also a Vice President of Zhongguancun Private Equity & Venture Capital Association (ZVCA) in Beijing. - Yong Yan是Alphavest Acquisition Corp的首席执行官，自2014年1月以来，他一直是总部位于上海的V-Stone Capital的合伙人，负责金融科技、区块链、大数据、医疗保健等领域的融资和私募股权投资。在加入四通资本之前，严博士是私募股权基金湖北宏泰产业投资基金的总经理兼CIO。此前，严博士是复星集团的董事总经理，复星集团是中国最大的民营企业集团之一，负责在线金融平台、证券化和金融科技等金融领域的投资，并建立内部的P2P平台。在加入复星集团之前，严博士曾在平安集团旗下的全球最大金融科技公司之一的陆金所担任新产品开发总经理。在2014年初移居中国之前，严博士在华尔街工作了近15年，其中在瑞士信贷工作了10年，担任全球结构性产品市场研究主管。严博士还曾在美林等其他金融公司工作。严博士是纽约TCFA（中国金融协会）的前任会长。他还是北京中关村私募股权&风险投资协会（ZVCA）的副总裁。严先生拥有阿拉巴马大学金融学博士学位，并且是CFA持证人。
- Yong Yan has served as a member of the board of directors since the Closing Date. Mr. Yan, AlphaVest's Chief Executive Officer until closing of the Business Combination, has been a partner at the Shanghai based V Stone Capital since January 2014, where he oversees fund raising and private equity investments in FinTech, BlockChain, Big Data, Healthcare and other areas. Prior to joining V Stone Capital, Dr. Yan was the General Manager and CIO of Hubei Hongtai Industrial Investment Fund, a private equity fund of funds. Previously, Dr. Yan was a Managing Director of Fosun Group, one of the largest private conglomerates in China, where he was in charge of investments in the financial sectors, such as online financial platform, securitization and fin tech, as well as building an in house P2P platform. Prior to joining the Fosun Group, Dr. Yan was the General Manager of New Product Development at Lufax, one of the world's largest fintech companies, owned by PingAn Group. Prior to moving to China in early 2014, Dr. Yan worked on Wall Street for almost 15 years, including 10 years at Credit Suisse, as the head of research of the global structured product market. Dr. Yan also worked at other financial firms such as Merrill Lynch. Dr. Yan is the ex President of TCFA (The Chinese Finance Association) in New York. He is also a Vice President of Zhongguancun Private Equity & Venture Capital Association (ZVCA) in Beijing.
- Jun Liu
-
刘俊，于2024年2月成为Curanex Pharmaceuticals Inc.首席执行官兼总裁，并于2024年6月成为董事会成员，重组后。刘先生拥有三十年的房地产开发经验，曾在中国多个城市开发超百万平方米的商住物业。他还拥有超过二十年的医药投资和研究经验，在香港和中国大陆经营中医诊所和私立医院。在制药领域，刘先生在研发方面担任领导角色，同时专注于植物和化学药物。自2020年起，他担任Duraviva Pharma Inc的总裁，在这家公司，他和他的直系亲属拥有多数股权和投票权，在那里他监督战略规划、业务发展和公司运营的整体管理。自2018年以来，他还提供咨询服务，并担任TCM Group Inc.的经理，这是他和他的家人持有多数股权所有权和投票权的另一个实体，在那里他就战略举措提供指导，管理关键客户关系，并确保提供高质量的咨询服务。刘先生于1988年获得东北师范大学学士学位。
Jun Liu became Curanex Pharmaceuticals Inc's Chief Executive Officer and President in February 2024, and a member of the Board in June 2024, upon the Reincorporation. Mr. Liu has three decades of real estate development experience, having developed over a million square meters of commercial and residential properties in various cities across China. He also has over twenty years of experience in pharmaceutical investment and research, operating traditional Chinese medicine clinics and private hospitals in Hong Kong and mainland China. In the pharmaceutical sector, Mr. Liu has taken leadership roles in research and development, focusing on both botanical and chemical drugs. Since 2020, he has served as the President of Duraviva Pharma Inc, a company in which he and his immediate family own a majority of the equity and voting power, where he oversees strategic planning, business development, and overall management of the company's operations. Since 2018, he has also offered consultancy services and served as the Manager of TCM Group Inc., another entity where he and his family hold a majority of the equity ownership and voting power, where he provides guidance on strategic initiatives, manages key client relationships, and ensures the delivery of high quality consultancy services. Mr. Liu received his BA in 1988 from Northeast Normal University. - 刘俊，于2024年2月成为Curanex Pharmaceuticals Inc.首席执行官兼总裁，并于2024年6月成为董事会成员，重组后。刘先生拥有三十年的房地产开发经验，曾在中国多个城市开发超百万平方米的商住物业。他还拥有超过二十年的医药投资和研究经验，在香港和中国大陆经营中医诊所和私立医院。在制药领域，刘先生在研发方面担任领导角色，同时专注于植物和化学药物。自2020年起，他担任Duraviva Pharma Inc的总裁，在这家公司，他和他的直系亲属拥有多数股权和投票权，在那里他监督战略规划、业务发展和公司运营的整体管理。自2018年以来，他还提供咨询服务，并担任TCM Group Inc.的经理，这是他和他的家人持有多数股权所有权和投票权的另一个实体，在那里他就战略举措提供指导，管理关键客户关系，并确保提供高质量的咨询服务。刘先生于1988年获得东北师范大学学士学位。
- Jun Liu became Curanex Pharmaceuticals Inc's Chief Executive Officer and President in February 2024, and a member of the Board in June 2024, upon the Reincorporation. Mr. Liu has three decades of real estate development experience, having developed over a million square meters of commercial and residential properties in various cities across China. He also has over twenty years of experience in pharmaceutical investment and research, operating traditional Chinese medicine clinics and private hospitals in Hong Kong and mainland China. In the pharmaceutical sector, Mr. Liu has taken leadership roles in research and development, focusing on both botanical and chemical drugs. Since 2020, he has served as the President of Duraviva Pharma Inc, a company in which he and his immediate family own a majority of the equity and voting power, where he oversees strategic planning, business development, and overall management of the company's operations. Since 2018, he has also offered consultancy services and served as the Manager of TCM Group Inc., another entity where he and his family hold a majority of the equity ownership and voting power, where he provides guidance on strategic initiatives, manages key client relationships, and ensures the delivery of high quality consultancy services. Mr. Liu received his BA in 1988 from Northeast Normal University.
- Huijuan Zhong
-
钟慧娟，于2024年6月重新组建后加入公司，担任首席科学官。她在制药行业拥有超过23年的经验，在药物物质和药物产品开发方面拥有知识和专长。自2021年起，她担任Karuna Therapeutics –百时美施贵宝旗下公司的分析开发副总监，提供范围广泛的基于风险的分析开发、方法验证和转移以及规范设置，以支持从IND I期到NDA的临床项目。2010年6月至2021年7月期间，她在Rhodes Pharmaceuticals担任首席科学家，担任领导职务，提供了她在从临床前开发到临床研究再到NDA505（b）（2）备案和商业化的药物物质和药物产品开发方面的专业知识。钟是美国科学促进会和美国化学学会会员、美国药物科学家协会和中美制药专业人员协会EC成员。钟博士是制药工业和化学领域多篇出版物的合著者。拥有东北大学分析化学博士后（1999-2001），1999年英国约克大学分析化学博士，1989年中国南京大学环境分析化学硕士，1986年中国南京大学有机化学理学学士学位。
Huijuan Zhong joined the Company as Chief Science Officer in June 2024, upon the Reincorporation, and was appointed as a member of the Board on February 1, 2025. She possesses over 23 years of experience in the pharmaceutical industry and has knowledge and expertise in drug substances and drug product development. Since 2021, she serves as associate director of Analytical Development at Karuna Therapeutics – a Bristol Myers Squibb company, providing a wide range of risk based analytical development, method validation and transfer, and specification setting to support clinical programs from IND Phase I to NDA. Between June 2010 and July 2021, she worked as Principal Scientist at Rhodes Pharmaceuticals, where she took a leadership role and provided her expertise in drug substance and drug product development from preclinical development through clinical studies to NDA505(b)(2) filings and commercialization. Dr. Zhong is a member of American Association for the Advancement of Science and American Chemical Society, American Association of Pharmaceutical Scientists and Sino American Pharmaceutical Professionals Association EC member. Dr. Zhong is a co author of many publications in the field of pharmaceutical industry and chemistry. She possesses a Postdoctoral in Analytical Chemistry from Northeastern University (1999 2001), a PhD in 1999 in Analytical Chemistry from, the University of York, UK, an MS in Environmental Analytical Chemistry from Nanjing University, China, in 1989, and BSc in Organic Chemistry from Nanjing University, China 1986. - 钟慧娟，于2024年6月重新组建后加入公司，担任首席科学官。她在制药行业拥有超过23年的经验，在药物物质和药物产品开发方面拥有知识和专长。自2021年起，她担任Karuna Therapeutics –百时美施贵宝旗下公司的分析开发副总监，提供范围广泛的基于风险的分析开发、方法验证和转移以及规范设置，以支持从IND I期到NDA的临床项目。2010年6月至2021年7月期间，她在Rhodes Pharmaceuticals担任首席科学家，担任领导职务，提供了她在从临床前开发到临床研究再到NDA505（b）（2）备案和商业化的药物物质和药物产品开发方面的专业知识。钟是美国科学促进会和美国化学学会会员、美国药物科学家协会和中美制药专业人员协会EC成员。钟博士是制药工业和化学领域多篇出版物的合著者。拥有东北大学分析化学博士后（1999-2001），1999年英国约克大学分析化学博士，1989年中国南京大学环境分析化学硕士，1986年中国南京大学有机化学理学学士学位。
- Huijuan Zhong joined the Company as Chief Science Officer in June 2024, upon the Reincorporation, and was appointed as a member of the Board on February 1, 2025. She possesses over 23 years of experience in the pharmaceutical industry and has knowledge and expertise in drug substances and drug product development. Since 2021, she serves as associate director of Analytical Development at Karuna Therapeutics – a Bristol Myers Squibb company, providing a wide range of risk based analytical development, method validation and transfer, and specification setting to support clinical programs from IND Phase I to NDA. Between June 2010 and July 2021, she worked as Principal Scientist at Rhodes Pharmaceuticals, where she took a leadership role and provided her expertise in drug substance and drug product development from preclinical development through clinical studies to NDA505(b)(2) filings and commercialization. Dr. Zhong is a member of American Association for the Advancement of Science and American Chemical Society, American Association of Pharmaceutical Scientists and Sino American Pharmaceutical Professionals Association EC member. Dr. Zhong is a co author of many publications in the field of pharmaceutical industry and chemistry. She possesses a Postdoctoral in Analytical Chemistry from Northeastern University (1999 2001), a PhD in 1999 in Analytical Chemistry from, the University of York, UK, an MS in Environmental Analytical Chemistry from Nanjing University, China, in 1989, and BSc in Organic Chemistry from Nanjing University, China 1986.
- Xiaohui Hao
-
郝晓辉，于2024年6月加入公司担任董事会成员，于重新注册成立时。自2021年1月起，他担任冠城钟表珠宝集团有限公司执行董事兼联席首席执行官，负责监督集团的战略方向、业务运营和风险管理，同时确保遵守监管要求和公司治理标准。2021年1月起担任本德拉银行（冠城钟表珠宝集团有限公司全资附属公司）董事会风险管理委员会成员，管理各类风险，包括管理风险、操作风险和流动性风险。2020年9月至2021年2月，担任中国春来教育集团（HK1069）董事Vice Chairman of the Board，提供战略指导，支持公司增长计划的制定和实施，确保有效的公司治理实践。同期还担任春来教育非执行董事、副董事长等职务。2018年2月至2020年4月，郝先生担任Yuanyin International Limited董事会主席兼首席执行官，负责制定公司整体发展战略，控制公司各项业务的发展风险。1988年获河南财经政法大学学士学位；1999年获厦门大学硕士学位；2003年获诺森比亚大学硕士学位。他是一名博士候选人。
Xiaohui Hao joined the Company as a member of the Board in June 2024, upon the Reincorporation. Since January 2021, he serves as the Executive Director & Co CEO of Citychamp Watch & Jewellery Group Limited, where he oversees the group's strategic direction, business operations, and risk management, while ensuring compliance with regulatory requirements and corporate governance standards. Since January 2021, he is serving as a member of the Risk Management Committee of the Board of Directors of Bendera Bank (the wholly owned subsidiary of Citychamp Watch & Jewellery Group Limited) to manage various risks, including management risk, operational risk and liquidity risk. From September 2020 to February 2021, he served as Vice Chairman of the board of directors of China Chunlai Education Group (HK1069), where he provided strategic guidance, supported the development and implementation of the company's growth plans, and ensured effective corporate governance practices. He also served as a non executive director and vice chairman of Chunlai Education during the same period. From February 2018 to April 2020, Mr. Hao served as Chairman of the Board of Directors and the CEO of Yuanyin International Limited, where he formulated the overall development strategy of the company and control the development risks of various business of the company. He received a bachelor's degree from Henan University in Economics and Law in 1988; master's degree from Xiamen University in 1999; master's degree from University of Northumbria in 2003. He is a PhD candidate. - 郝晓辉，于2024年6月加入公司担任董事会成员，于重新注册成立时。自2021年1月起，他担任冠城钟表珠宝集团有限公司执行董事兼联席首席执行官，负责监督集团的战略方向、业务运营和风险管理，同时确保遵守监管要求和公司治理标准。2021年1月起担任本德拉银行（冠城钟表珠宝集团有限公司全资附属公司）董事会风险管理委员会成员，管理各类风险，包括管理风险、操作风险和流动性风险。2020年9月至2021年2月，担任中国春来教育集团（HK1069）董事Vice Chairman of the Board，提供战略指导，支持公司增长计划的制定和实施，确保有效的公司治理实践。同期还担任春来教育非执行董事、副董事长等职务。2018年2月至2020年4月，郝先生担任Yuanyin International Limited董事会主席兼首席执行官，负责制定公司整体发展战略，控制公司各项业务的发展风险。1988年获河南财经政法大学学士学位；1999年获厦门大学硕士学位；2003年获诺森比亚大学硕士学位。他是一名博士候选人。
- Xiaohui Hao joined the Company as a member of the Board in June 2024, upon the Reincorporation. Since January 2021, he serves as the Executive Director & Co CEO of Citychamp Watch & Jewellery Group Limited, where he oversees the group's strategic direction, business operations, and risk management, while ensuring compliance with regulatory requirements and corporate governance standards. Since January 2021, he is serving as a member of the Risk Management Committee of the Board of Directors of Bendera Bank (the wholly owned subsidiary of Citychamp Watch & Jewellery Group Limited) to manage various risks, including management risk, operational risk and liquidity risk. From September 2020 to February 2021, he served as Vice Chairman of the board of directors of China Chunlai Education Group (HK1069), where he provided strategic guidance, supported the development and implementation of the company's growth plans, and ensured effective corporate governance practices. He also served as a non executive director and vice chairman of Chunlai Education during the same period. From February 2018 to April 2020, Mr. Hao served as Chairman of the Board of Directors and the CEO of Yuanyin International Limited, where he formulated the overall development strategy of the company and control the development risks of various business of the company. He received a bachelor's degree from Henan University in Economics and Law in 1988; master's degree from Xiamen University in 1999; master's degree from University of Northumbria in 2003. He is a PhD candidate.
- Helen Hsu
-
Helen Hsu，于2024年11月1日加入公司担任董事会成员，因杜燕明辞职。徐博士在制药行业、学术界和临床环境中拥有超过30年的经验。自2023年12月起，许博士担任Phamaron Clinical Services的医学科学副总裁，利用她在肿瘤学研究、医疗事务和临床运营方面的深厚专业知识来推动创新项目。2021年3月至2023年7月，许博士在IPSEN BioPharma Epizyme Pharmaceutical担任全球肿瘤临床开发高级医学总监。2015年至2020年，她在美国一家癌症中心和哈佛医学院附属的一家国际癌症医院担任肿瘤学/血液学研究主管。她的临床研究和医疗事务经历跨越了2000年至2013年的GSK、诺华和BI全球制药。她还曾担任生物技术、CRO、医疗器械公司、癌症中心和医疗投资集团的医疗顾问、CMO和战略顾问超过10年。许博士获得中国东南大学医学院医学博士学位，密歇根州立大学分子生物学和临床实验室科学理学硕士学位。除了在中国的临床实践，她还在纽约的阿尔伯特·爱因斯坦医学院和北岸大学医院接受了医学科学和基因搜索方面的培训。
Helen Hsu joined the Company as a member of the Board on November 1, 2024, upon resignation of Yanming Du. Dr. Hsu has over 30 years of experience in the pharmaceutical industry, academia, and clinical settings. Since December 2023, Dr. Hsu has served as the VP of Medical Science at Phamaron Clinical Services, where she leverages her deep expertise in oncology research, medical affairs, and clinical operations to drive innovative programs. From March 2021 to July 2023, Dr. Hsu held the role of Senior Medical Director, Global Oncology Clinical Development at IPSEN BioPharma Epizyme Pharmaceutical. From 2015 to 2020, she was the Head of Oncology/Hematology Research at an US Cancer Centers and an International Cancer Hospital affiliated with Harvard Medical School. Her clinical research and medical affairs experiences has spanned in GSK, Novartis and BI global pharmaceuticals from 2000 2013. She also served as a Medical Consultant, CMO, and Strategy Advisor for Biotech, CRO, Medical Device companies, Cancer Centers, and Healthcare Investment Groups for over 10 years. Dr. Hsu received an MD degree from Southeast University Medical School in China and a Master of Science in Molecular Biology and Clinical Lab Science from Michigan State University. In addition to her clinical practice in China, she has been trained in medical science and genetic search at Albert Einstein College of Medicine and North Shore University Hospital in NY. - Helen Hsu，于2024年11月1日加入公司担任董事会成员，因杜燕明辞职。徐博士在制药行业、学术界和临床环境中拥有超过30年的经验。自2023年12月起，许博士担任Phamaron Clinical Services的医学科学副总裁，利用她在肿瘤学研究、医疗事务和临床运营方面的深厚专业知识来推动创新项目。2021年3月至2023年7月，许博士在IPSEN BioPharma Epizyme Pharmaceutical担任全球肿瘤临床开发高级医学总监。2015年至2020年，她在美国一家癌症中心和哈佛医学院附属的一家国际癌症医院担任肿瘤学/血液学研究主管。她的临床研究和医疗事务经历跨越了2000年至2013年的GSK、诺华和BI全球制药。她还曾担任生物技术、CRO、医疗器械公司、癌症中心和医疗投资集团的医疗顾问、CMO和战略顾问超过10年。许博士获得中国东南大学医学院医学博士学位，密歇根州立大学分子生物学和临床实验室科学理学硕士学位。除了在中国的临床实践，她还在纽约的阿尔伯特·爱因斯坦医学院和北岸大学医院接受了医学科学和基因搜索方面的培训。
- Helen Hsu joined the Company as a member of the Board on November 1, 2024, upon resignation of Yanming Du. Dr. Hsu has over 30 years of experience in the pharmaceutical industry, academia, and clinical settings. Since December 2023, Dr. Hsu has served as the VP of Medical Science at Phamaron Clinical Services, where she leverages her deep expertise in oncology research, medical affairs, and clinical operations to drive innovative programs. From March 2021 to July 2023, Dr. Hsu held the role of Senior Medical Director, Global Oncology Clinical Development at IPSEN BioPharma Epizyme Pharmaceutical. From 2015 to 2020, she was the Head of Oncology/Hematology Research at an US Cancer Centers and an International Cancer Hospital affiliated with Harvard Medical School. Her clinical research and medical affairs experiences has spanned in GSK, Novartis and BI global pharmaceuticals from 2000 2013. She also served as a Medical Consultant, CMO, and Strategy Advisor for Biotech, CRO, Medical Device companies, Cancer Centers, and Healthcare Investment Groups for over 10 years. Dr. Hsu received an MD degree from Southeast University Medical School in China and a Master of Science in Molecular Biology and Clinical Lab Science from Michigan State University. In addition to her clinical practice in China, she has been trained in medical science and genetic search at Albert Einstein College of Medicine and North Shore University Hospital in NY.
高管简历
中英对照 | 中文 | 英文- Jun Liu
刘俊，于2024年2月成为Curanex Pharmaceuticals Inc.首席执行官兼总裁，并于2024年6月成为董事会成员，重组后。刘先生拥有三十年的房地产开发经验，曾在中国多个城市开发超百万平方米的商住物业。他还拥有超过二十年的医药投资和研究经验，在香港和中国大陆经营中医诊所和私立医院。在制药领域，刘先生在研发方面担任领导角色，同时专注于植物和化学药物。自2020年起，他担任Duraviva Pharma Inc的总裁，在这家公司，他和他的直系亲属拥有多数股权和投票权，在那里他监督战略规划、业务发展和公司运营的整体管理。自2018年以来，他还提供咨询服务，并担任TCM Group Inc.的经理，这是他和他的家人持有多数股权所有权和投票权的另一个实体，在那里他就战略举措提供指导，管理关键客户关系，并确保提供高质量的咨询服务。刘先生于1988年获得东北师范大学学士学位。
Jun Liu became Curanex Pharmaceuticals Inc's Chief Executive Officer and President in February 2024, and a member of the Board in June 2024, upon the Reincorporation. Mr. Liu has three decades of real estate development experience, having developed over a million square meters of commercial and residential properties in various cities across China. He also has over twenty years of experience in pharmaceutical investment and research, operating traditional Chinese medicine clinics and private hospitals in Hong Kong and mainland China. In the pharmaceutical sector, Mr. Liu has taken leadership roles in research and development, focusing on both botanical and chemical drugs. Since 2020, he has served as the President of Duraviva Pharma Inc, a company in which he and his immediate family own a majority of the equity and voting power, where he oversees strategic planning, business development, and overall management of the company's operations. Since 2018, he has also offered consultancy services and served as the Manager of TCM Group Inc., another entity where he and his family hold a majority of the equity ownership and voting power, where he provides guidance on strategic initiatives, manages key client relationships, and ensures the delivery of high quality consultancy services. Mr. Liu received his BA in 1988 from Northeast Normal University.- 刘俊，于2024年2月成为Curanex Pharmaceuticals Inc.首席执行官兼总裁，并于2024年6月成为董事会成员，重组后。刘先生拥有三十年的房地产开发经验，曾在中国多个城市开发超百万平方米的商住物业。他还拥有超过二十年的医药投资和研究经验，在香港和中国大陆经营中医诊所和私立医院。在制药领域，刘先生在研发方面担任领导角色，同时专注于植物和化学药物。自2020年起，他担任Duraviva Pharma Inc的总裁，在这家公司，他和他的直系亲属拥有多数股权和投票权，在那里他监督战略规划、业务发展和公司运营的整体管理。自2018年以来，他还提供咨询服务，并担任TCM Group Inc.的经理，这是他和他的家人持有多数股权所有权和投票权的另一个实体，在那里他就战略举措提供指导，管理关键客户关系，并确保提供高质量的咨询服务。刘先生于1988年获得东北师范大学学士学位。
- Jun Liu became Curanex Pharmaceuticals Inc's Chief Executive Officer and President in February 2024, and a member of the Board in June 2024, upon the Reincorporation. Mr. Liu has three decades of real estate development experience, having developed over a million square meters of commercial and residential properties in various cities across China. He also has over twenty years of experience in pharmaceutical investment and research, operating traditional Chinese medicine clinics and private hospitals in Hong Kong and mainland China. In the pharmaceutical sector, Mr. Liu has taken leadership roles in research and development, focusing on both botanical and chemical drugs. Since 2020, he has served as the President of Duraviva Pharma Inc, a company in which he and his immediate family own a majority of the equity and voting power, where he oversees strategic planning, business development, and overall management of the company's operations. Since 2018, he has also offered consultancy services and served as the Manager of TCM Group Inc., another entity where he and his family hold a majority of the equity ownership and voting power, where he provides guidance on strategic initiatives, manages key client relationships, and ensures the delivery of high quality consultancy services. Mr. Liu received his BA in 1988 from Northeast Normal University.
- Dian Ying Jing
典应晶，自成立以来一直担任Curanex Pharmaceuticals Inc.董事兼秘书。从2018年到2024年2月，她还担任Curanex Pharmaceuticals Inc.首席执行官兼总裁，从2018年到2024年6月，她担任Curanex Pharmaceuticals Inc.财务主管，负责监督公司的财务运营，管理与投资者和利益相关者的关系，并提供战略领导，以推动公司的增长和发展。她还担任Duraviva的董事。她提供植物和化学药物的研发服务。自2017年起，她担任TCM Group Inc总裁，为草药产品提供咨询服务。荆女士于1989年获得东北师范大学学士学位。
Dian Ying Jing has been Curanex Pharmaceuticals Inc's Secretary since inception. From inception to January 31, 2025, she also served as Curanex Pharmaceuticals Inc's director. From 2018 until February 2024, she also served as Curanex Pharmaceuticals Inc's Chief Executive Officer and President and from 2018 until June 2024, she served as Curanex Pharmaceuticals Inc's Treasurer, where she oversaw the Company's financial operations, managed relationships with investors and stakeholders, and provided strategic leadership to drive the Company's growth and development. She is the wife of the Company's Chief Executive Officer and President, Jun Liu, and together with him and their son, Chang Liu, owns a majority of the equity ownership and the voting power of the Company. She also serves as the director of Duraviva. She provides R&D services for botanical and chemical drugs. Since 2017, she serves as President of TCM Group Inc, where she provides consultation service for herbal products. Ms. Jing holds a bachelor's degree from Northeast Normal University in 1989.- 典应晶，自成立以来一直担任Curanex Pharmaceuticals Inc.董事兼秘书。从2018年到2024年2月，她还担任Curanex Pharmaceuticals Inc.首席执行官兼总裁，从2018年到2024年6月，她担任Curanex Pharmaceuticals Inc.财务主管，负责监督公司的财务运营，管理与投资者和利益相关者的关系，并提供战略领导，以推动公司的增长和发展。她还担任Duraviva的董事。她提供植物和化学药物的研发服务。自2017年起，她担任TCM Group Inc总裁，为草药产品提供咨询服务。荆女士于1989年获得东北师范大学学士学位。
- Dian Ying Jing has been Curanex Pharmaceuticals Inc's Secretary since inception. From inception to January 31, 2025, she also served as Curanex Pharmaceuticals Inc's director. From 2018 until February 2024, she also served as Curanex Pharmaceuticals Inc's Chief Executive Officer and President and from 2018 until June 2024, she served as Curanex Pharmaceuticals Inc's Treasurer, where she oversaw the Company's financial operations, managed relationships with investors and stakeholders, and provided strategic leadership to drive the Company's growth and development. She is the wife of the Company's Chief Executive Officer and President, Jun Liu, and together with him and their son, Chang Liu, owns a majority of the equity ownership and the voting power of the Company. She also serves as the director of Duraviva. She provides R&D services for botanical and chemical drugs. Since 2017, she serves as President of TCM Group Inc, where she provides consultation service for herbal products. Ms. Jing holds a bachelor's degree from Northeast Normal University in 1989.
- Huijuan Zhong
钟慧娟，于2024年6月重新组建后加入公司，担任首席科学官。她在制药行业拥有超过23年的经验，在药物物质和药物产品开发方面拥有知识和专长。自2021年起，她担任Karuna Therapeutics –百时美施贵宝旗下公司的分析开发副总监，提供范围广泛的基于风险的分析开发、方法验证和转移以及规范设置，以支持从IND I期到NDA的临床项目。2010年6月至2021年7月期间，她在Rhodes Pharmaceuticals担任首席科学家，担任领导职务，提供了她在从临床前开发到临床研究再到NDA505（b）（2）备案和商业化的药物物质和药物产品开发方面的专业知识。钟是美国科学促进会和美国化学学会会员、美国药物科学家协会和中美制药专业人员协会EC成员。钟博士是制药工业和化学领域多篇出版物的合著者。拥有东北大学分析化学博士后（1999-2001），1999年英国约克大学分析化学博士，1989年中国南京大学环境分析化学硕士，1986年中国南京大学有机化学理学学士学位。
Huijuan Zhong joined the Company as Chief Science Officer in June 2024, upon the Reincorporation, and was appointed as a member of the Board on February 1, 2025. She possesses over 23 years of experience in the pharmaceutical industry and has knowledge and expertise in drug substances and drug product development. Since 2021, she serves as associate director of Analytical Development at Karuna Therapeutics – a Bristol Myers Squibb company, providing a wide range of risk based analytical development, method validation and transfer, and specification setting to support clinical programs from IND Phase I to NDA. Between June 2010 and July 2021, she worked as Principal Scientist at Rhodes Pharmaceuticals, where she took a leadership role and provided her expertise in drug substance and drug product development from preclinical development through clinical studies to NDA505(b)(2) filings and commercialization. Dr. Zhong is a member of American Association for the Advancement of Science and American Chemical Society, American Association of Pharmaceutical Scientists and Sino American Pharmaceutical Professionals Association EC member. Dr. Zhong is a co author of many publications in the field of pharmaceutical industry and chemistry. She possesses a Postdoctoral in Analytical Chemistry from Northeastern University (1999 2001), a PhD in 1999 in Analytical Chemistry from, the University of York, UK, an MS in Environmental Analytical Chemistry from Nanjing University, China, in 1989, and BSc in Organic Chemistry from Nanjing University, China 1986.- 钟慧娟，于2024年6月重新组建后加入公司，担任首席科学官。她在制药行业拥有超过23年的经验，在药物物质和药物产品开发方面拥有知识和专长。自2021年起，她担任Karuna Therapeutics –百时美施贵宝旗下公司的分析开发副总监，提供范围广泛的基于风险的分析开发、方法验证和转移以及规范设置，以支持从IND I期到NDA的临床项目。2010年6月至2021年7月期间，她在Rhodes Pharmaceuticals担任首席科学家，担任领导职务，提供了她在从临床前开发到临床研究再到NDA505（b）（2）备案和商业化的药物物质和药物产品开发方面的专业知识。钟是美国科学促进会和美国化学学会会员、美国药物科学家协会和中美制药专业人员协会EC成员。钟博士是制药工业和化学领域多篇出版物的合著者。拥有东北大学分析化学博士后（1999-2001），1999年英国约克大学分析化学博士，1989年中国南京大学环境分析化学硕士，1986年中国南京大学有机化学理学学士学位。
- Huijuan Zhong joined the Company as Chief Science Officer in June 2024, upon the Reincorporation, and was appointed as a member of the Board on February 1, 2025. She possesses over 23 years of experience in the pharmaceutical industry and has knowledge and expertise in drug substances and drug product development. Since 2021, she serves as associate director of Analytical Development at Karuna Therapeutics – a Bristol Myers Squibb company, providing a wide range of risk based analytical development, method validation and transfer, and specification setting to support clinical programs from IND Phase I to NDA. Between June 2010 and July 2021, she worked as Principal Scientist at Rhodes Pharmaceuticals, where she took a leadership role and provided her expertise in drug substance and drug product development from preclinical development through clinical studies to NDA505(b)(2) filings and commercialization. Dr. Zhong is a member of American Association for the Advancement of Science and American Chemical Society, American Association of Pharmaceutical Scientists and Sino American Pharmaceutical Professionals Association EC member. Dr. Zhong is a co author of many publications in the field of pharmaceutical industry and chemistry. She possesses a Postdoctoral in Analytical Chemistry from Northeastern University (1999 2001), a PhD in 1999 in Analytical Chemistry from, the University of York, UK, an MS in Environmental Analytical Chemistry from Nanjing University, China, in 1989, and BSc in Organic Chemistry from Nanjing University, China 1986.
- Liqin Xie
Liqin Xie，于2024年6月加入公司，担任首席运营官，当时重新注册成立。凭借在大型制药公司（再生元制药）和初创生物技术公司（Surrozen）超过15年的经验，谢博士在针对多种疾病的药物发现和开发方面拥有深厚的专业知识以及项目领导力，他拥有强大的科学敏锐性，发表了50多篇论文和5项专利。2018-2023年，谢博士在Surrozen公司担任首席科学家职务，担任炎症性肠病体内药理组组长，设计并进行药代动力学/药效学实验和毒理学分析，为IND备案准备文件，并引领一流的溃疡性结肠炎药物从发现到IND。Dr。谢拥有北京中医药大学医学博士学位、中国空间医学工程研究所医学硕士学位（重点研究代谢学）、纽约州立大学石溪分校生物医学工程博士学位。
Liqin Xie joined the Company as the Chief Operating Officer in June 2024, upon the Reincorporation. With over 15 years of experience across big pharma (Regeneron) and startup biotech (Surrozen), Dr. Xie possesses deep expertise in drug discovery and development for multiple diseases and program leadership, and he has a strong scientific acumen with over 50 publications and 5 patents. From 2018 to 2023, Dr. Xie held the position of Principal Scientist at Surrozen Inc., where he served as the team leader of Inflammatory Bowel Disease in vivo Pharmacology group, designed and conducted Pharmacokinetic/Pharmacodynamic experiments and toxicology analysis, prepared documents for IND filing, and led a first in class Ulcerative Colitis drug from discovery to IND. Dr. Xie holds an M.D. from Beijing University of Chinese Medicine, an M.S. in Medicine (with a focus on Metabolism) from the Institute of Space Medico Engineering of China, and a Ph.D. in Biomedical Engineering from the State University of New York at Stony Brook.- Liqin Xie，于2024年6月加入公司，担任首席运营官，当时重新注册成立。凭借在大型制药公司（再生元制药）和初创生物技术公司（Surrozen）超过15年的经验，谢博士在针对多种疾病的药物发现和开发方面拥有深厚的专业知识以及项目领导力，他拥有强大的科学敏锐性，发表了50多篇论文和5项专利。2018-2023年，谢博士在Surrozen公司担任首席科学家职务，担任炎症性肠病体内药理组组长，设计并进行药代动力学/药效学实验和毒理学分析，为IND备案准备文件，并引领一流的溃疡性结肠炎药物从发现到IND。Dr。谢拥有北京中医药大学医学博士学位、中国空间医学工程研究所医学硕士学位（重点研究代谢学）、纽约州立大学石溪分校生物医学工程博士学位。
- Liqin Xie joined the Company as the Chief Operating Officer in June 2024, upon the Reincorporation. With over 15 years of experience across big pharma (Regeneron) and startup biotech (Surrozen), Dr. Xie possesses deep expertise in drug discovery and development for multiple diseases and program leadership, and he has a strong scientific acumen with over 50 publications and 5 patents. From 2018 to 2023, Dr. Xie held the position of Principal Scientist at Surrozen Inc., where he served as the team leader of Inflammatory Bowel Disease in vivo Pharmacology group, designed and conducted Pharmacokinetic/Pharmacodynamic experiments and toxicology analysis, prepared documents for IND filing, and led a first in class Ulcerative Colitis drug from discovery to IND. Dr. Xie holds an M.D. from Beijing University of Chinese Medicine, an M.S. in Medicine (with a focus on Metabolism) from the Institute of Space Medico Engineering of China, and a Ph.D. in Biomedical Engineering from the State University of New York at Stony Brook.
- Ning Zhang
Ning Zhang，于2024年6月在重新注册成立时加入公司担任首席技术官。在推动医药技术创新和进步的中医药领域具有丰富的经验。自2014年起，张博士担任黑龙江中医药大学中医药教授，于2018年担任博士生导师，领导研究项目、指导博士生，并与行业合作伙伴合作，将研究成果转化为实际应用。张教授以学术身份将研究重点放在活性药物成分的提取和鉴定上，同时增强药物剂型和药代动力学。Zhang于1993年获得上海医科大学学士学位；于2003年和2006年分别获得黑龙江中医药大学生物医学和中医药硕士和博士学位。凭借其广泛的学术背景和对推进制药科学的奉献精神，董事会认为，张博士在推动Curanex的技术创新和卓越方面发挥着至关重要的作用。
Ning Zhang joined the Company as the Chief Technology Officer in June 2024, upon the Reincorporation. He has extensive experience in traditional Chinese medicine that drives innovation and advancement in pharmaceutical technologies. Since 2014, Dr. Zhang has served as a Professor of Traditional Chinese Medicine at Heilongjiang University of Chinese Medicine, assuming the role of Doctoral Supervisor in 2018, where he leads research projects, supervises doctoral students, and collaborates with industry partners to translate research findings into practical applications. In his academic capacity, Professor Zhang focuses his research on the extraction and identification of active pharmaceutical ingredients, alongside enhancing pharmaceutical dosage forms and pharmacokinetics. Dr. Zhang holds a BA degree from Shanghai Medical University in 1993; Master's and Doctoral degrees in Biomedicine and Chinese Medicine from Heilongjiang University of Chinese Medicine in 2003 and 2006, respectively.- Ning Zhang，于2024年6月在重新注册成立时加入公司担任首席技术官。在推动医药技术创新和进步的中医药领域具有丰富的经验。自2014年起，张博士担任黑龙江中医药大学中医药教授，于2018年担任博士生导师，领导研究项目、指导博士生，并与行业合作伙伴合作，将研究成果转化为实际应用。张教授以学术身份将研究重点放在活性药物成分的提取和鉴定上，同时增强药物剂型和药代动力学。Zhang于1993年获得上海医科大学学士学位；于2003年和2006年分别获得黑龙江中医药大学生物医学和中医药硕士和博士学位。凭借其广泛的学术背景和对推进制药科学的奉献精神，董事会认为，张博士在推动Curanex的技术创新和卓越方面发挥着至关重要的作用。
- Ning Zhang joined the Company as the Chief Technology Officer in June 2024, upon the Reincorporation. He has extensive experience in traditional Chinese medicine that drives innovation and advancement in pharmaceutical technologies. Since 2014, Dr. Zhang has served as a Professor of Traditional Chinese Medicine at Heilongjiang University of Chinese Medicine, assuming the role of Doctoral Supervisor in 2018, where he leads research projects, supervises doctoral students, and collaborates with industry partners to translate research findings into practical applications. In his academic capacity, Professor Zhang focuses his research on the extraction and identification of active pharmaceutical ingredients, alongside enhancing pharmaceutical dosage forms and pharmacokinetics. Dr. Zhang holds a BA degree from Shanghai Medical University in 1993; Master's and Doctoral degrees in Biomedicine and Chinese Medicine from Heilongjiang University of Chinese Medicine in 2003 and 2006, respectively.
- Wanjun Zhang
Wanjun Zhang，为中小型公司提供财务咨询和会计服务，专注于财务报告、合规和业务战略。2017年7月至2020年7月期间，张先生担任北京华夏汇通零用贷款有限公司的财务总监，提供全面的财务、合规和会计服务。2010年8月至2016年2月期间，张先生发挥了重要的领导作用，担任北京完美时空网络技术（北京）软件有限公司的财务总监，该公司在2007年至2015年期间是一家在纳斯达克上市的公开交易SEC报告公司，股票代码为“PWRD”。张先生拥有中国北京中央财经大学会计学学士学位。
Wanjun Zhang was appointed as Curanex Pharmaceuticals Inc's Chief Financial Officer and Treasurer of the Company, effective January 1, 2026. He has over 20 years of financial and accounting related experience, specializing in financial reporting, compliance, and business strategy. Before joining Curanex, from July 2020, he provided financial consulting and accounting services to small and medium size companies, focusing on financial reporting, compliance and business strategy. Between July 2017 and July 2020, Mr. Zhang served as the finance director of Beijing Huaxiahuitong Petty Loan Co. Ltd., where he provided full financial, compliance and accounting services, and between August 2010 and February 2016, Mr. Zhang played a significant leadership role, serving as the finance director of Perfect World (Beijing) Software Co., Ltd., which between 2007 and 2015 was a publicly traded SEC reporting company listed on Nasdaq under the ticker symbol "PWRD." Mr. Zhang holds a Bachelor's degree in Accounting from the Central University of Finance and Economics in Beijing, China.- Wanjun Zhang，为中小型公司提供财务咨询和会计服务，专注于财务报告、合规和业务战略。2017年7月至2020年7月期间，张先生担任北京华夏汇通零用贷款有限公司的财务总监，提供全面的财务、合规和会计服务。2010年8月至2016年2月期间，张先生发挥了重要的领导作用，担任北京完美时空网络技术（北京）软件有限公司的财务总监，该公司在2007年至2015年期间是一家在纳斯达克上市的公开交易SEC报告公司，股票代码为“PWRD”。张先生拥有中国北京中央财经大学会计学学士学位。
- Wanjun Zhang was appointed as Curanex Pharmaceuticals Inc's Chief Financial Officer and Treasurer of the Company, effective January 1, 2026. He has over 20 years of financial and accounting related experience, specializing in financial reporting, compliance, and business strategy. Before joining Curanex, from July 2020, he provided financial consulting and accounting services to small and medium size companies, focusing on financial reporting, compliance and business strategy. Between July 2017 and July 2020, Mr. Zhang served as the finance director of Beijing Huaxiahuitong Petty Loan Co. Ltd., where he provided full financial, compliance and accounting services, and between August 2010 and February 2016, Mr. Zhang played a significant leadership role, serving as the finance director of Perfect World (Beijing) Software Co., Ltd., which between 2007 and 2015 was a publicly traded SEC reporting company listed on Nasdaq under the ticker symbol "PWRD." Mr. Zhang holds a Bachelor's degree in Accounting from the Central University of Finance and Economics in Beijing, China.